BCIQ Profiles

Company Profile Report
1210 Evelo
                                                   1BioCentury & Getty Images

Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Dec 10, 2020 | 11:52 PM GMT

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity.

Evelo Biosciences Inc. (NASDAQ:EVLO) has gained

Read the full 794 word article

How to gain access

Continue reading with a
two-week free trial.